Results 1 - 10 of 30 : 1 2 3 Next
The drugmaker gets its licenses to distribute controlled substances reinstated.
King's Unstoppable Urge to Merge
Your potential acquisition isn't interested? Go for the hostile takeover!
These stocks are bucking the trend.
The pharmaceutical makes an all-in bet on an unproven market.
The Worry-Free Way to Manage Your Retirement
Know the tricks to drawing down your savings.
Looking for a megatrend? Then follow the leaders.
A Potentially Painless PDUFA Date
King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
It picks up an asset that's more than half its size.
Celgene Savors the Schadenfreude
Bad news for a rival is a bonanza for the drugmaker.
DURECT's Intriguing Little Orphan
An exciting pain drug inches onward in development.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK